We used the following primary antibodies: mouse monoclonal IgG2a
recognizing α-SM actin,
17 affinity-purified rabbit
polyclonal IgG against desmin,
18 affinity-purified rabbit
polyclonal IgG recognizing SM myosin heavy chain types 1 and
2,
19 mouse monoclonal IgG1 against vimentin, rabbit
polyclonal IgG specific for glial fibrillary-associated protein (GFAP),
mouse monoclonal IgG1 recognizing all types of cytokeratin
(anti-pankeratin, Lu-5, all from Dako, Glostrup, Denmark), mouse
monoclonal IgG1 specific for ED-A type III domain of cellular FN
(IST-9, gift from Luciano Zardi, National Institute for Cancer
Research, Genova, Italy)
20 , affinity-purified chicken
polyclonal IgG against TGF-β1 (R&D, Minneapolis, MN), and two
affinity-purified rabbit polyclonal IgGs against TGF-β receptor I and
II (TGF-βRI and II; Santa Cruz Biotechnology, Santa Cruz, CA).